Approval · Notice of Compliance 321 · 2002
ZYBAN TABLETS: Notice of Compliance 321
Issued June 10, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 321
- Date
- June 10, 2002
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph: new safety information on use in patients with liver or renal impairment
- Therapeutic class
- Smoking cessation aid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYBAN TABLETS | Not yet assigned | — |
Medicinal ingredients
- BUPROPION HYDROCHLORIDE 150 MG per TAB